Skip to main content
Premium Trial:

Request an Annual Quote

CovalX Inks Deal with ASPEC to Sell Protein Analysis Tech in Greater China Market

Premium

CovalX and ASPEC Technologies said this week that they have signed a distribution agreement to sell CovalX's mass spec-based protein interaction and protein characterization tools into the greater China market.

The agreement combines CovalX's products with ASPEC's commercial partnerships and infrastructure in this region, providing ASPEC customers with exclusive access to CovalX's protein analysis tools, the companies said.

CovalX's MALDI mass spec-based HM3 platform allows for protein-protein analyses including stoichiometry, biotherapeutic aggregation, epitope mapping, and immunocomplex characterization.

The deal covers ASPEC customers in mainland China, Hong Kong, Macau and Taiwan. Financial and other terms were not disclosed.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.